


# P2X Receptor

## P2XRs

HDAC Inhibitor:  
Vorinostat (SAHA)




HDAC (Histone deacetylase)


HDAC (Histone deacetylase)


human P2X5, and P2X7) exhibit multiple open states in response to ATP, characterized by a time-dependent increase in the permeabilities of large organic ions and nucleotide binding dyes.


## P2X Receptor Inhibitors & Modulators


<p><b>A 438079</b></p> <p style="text-align: right;">Cat. No.: HY-15488</p> <p><b>Bioactivity:</b> A 438079 is a potent, and selective <b>P2X<sub>7</sub></b> receptor antagonist with pIC<sub>50</sub> of 6.9.</p> <p><b>Purity:</b> 99.64%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10 mg, 50 mg</p> 	<p><b>A 438079 (hydrochloride)</b></p> <p style="text-align: right;">Cat. No.: HY-15488A</p> <p><b>Bioactivity:</b> A 438079 (hydrochloride) is a potent, and selective <b>P2X<sub>7</sub></b> receptor antagonist with pIC<sub>50</sub> of 6.9.</p> <p><b>Purity:</b> 99.88%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10mM x 1mL in Water, 10 mg, 50 mg</p> 
<p><b>A 839977</b></p> <p style="text-align: right;">Cat. No.: HY-13954</p> <p><b>Bioactivity:</b> A-839977 is a novel and selective P2X7 antagonist; blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20, 42 and 150 nM respectively).</p> <p><b>Purity:</b> 98.05%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 	<p><b>A-317491</b></p> <p style="text-align: right;">Cat. No.: HY-15568</p> <p><b>Bioactivity:</b> A-317491 is a non-nucleotide P2X3 and P2X2/3 receptor antagonist, which inhibits calcium flux mediated by the receptors. IC50 value: Target: P2X2/3 It is known that P2X3 and P2X2/3 receptors stimulate the pronociceptive effects of ATP upon activation. Studies indicate that the P2X3 receptor...</p> <p><b>Purity:</b> 99.18%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p><b>A-317491 sodium salt hydrate</b></p> <p style="text-align: right;">Cat. No.: HY-15568A</p> <p><b>Bioactivity:</b> A-317491 is a non-nucleotide P2X3 and P2X2/3 receptor antagonist, which inhibits calcium flux mediated by the receptors. IC50 value: Target: P2X2/3 receptor It is known that P2X3 and P2X2/3 receptors stimulate the pronociceptive effects of ATP upon activation. Studies indicate that the P2X3...</p> <p><b>Purity:</b> 99.65%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg</p> 	<p><b>A-740003</b></p> <p style="text-align: right;">Cat. No.: HY-50697</p> <p><b>Bioactivity:</b> A-740003 is a potent, selective and competitive <b>P2X7</b> receptor antagonist with IC<sub>50</sub> values are 18 and 40 nM for rat and human P2X7 receptors, respectively.</p> <p><b>Purity:</b> 98.91%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 
<p><b>A-804598</b></p> <p style="text-align: right;">Cat. No.: HY-100483</p> <p><b>Bioactivity:</b> A-804598 is a novel, competitive, and selective P2X7 receptor antagonist with IC50 of 10 nM, 9 nM and 11 nM in rat, mouse and human P2X7 receptors respectively. In vitro: A-804598 potentially blocked IL-1β release in the THP-1 cells (IC50 of 8.5 nM). A-804598 also blocked agonist-evoked pore formation in...</p> <p><b>Purity:</b> 98.83%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p><b>AF-353 (Ro-4)</b></p> <p style="text-align: right;">Cat. No.: HY-14483</p> <p><b>Bioactivity:</b> AF-353 is a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist, inhibits human and rat P2X3 (pIC50= 8.0).</p> <p><b>Purity:</b> 98.95%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</p> 
<p><b>ATP disodium salt (Disodium adenosine triphosphate; Adenosine 5'-triphosphate disodium salt)</b></p> <p style="text-align: right;">Cat. No.: HY-B0345A</p> <p><b>Bioactivity:</b> ATP is a phosphate-group donor for substrate activation in metabolic reactions and the coenzyme for a large number of kinases.</p> <p><b>Purity:</b> 98.0%</p> <p><b>Clinical Data:</b> No Development Reported</p> <p><b>Size:</b> 10mM x 1mL in Water, 1 g, 5 g</p> 	<p><b>AZD9056 hydrochloride</b></p> <p style="text-align: right;">Cat. No.: HY-19427A</p> <p><b>Bioactivity:</b> AZD9056 is a selective orally active inhibitor of <b>P2X7</b> which plays a significant role in inflammation and pain-causing diseases.</p> <p><b>Purity:</b> 98.10%</p> <p><b>Clinical Data:</b> Phase 2</p> <p><b>Size:</b> 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</p> 


<b>CE-224535</b> (PF-04905428)	Cat. No.: HY-15487
<b>Bioactivity:</b> CE-224535 is a selective <b>P2X<sub>7</sub> receptor</b> antagonist.	
<b>Purity:</b> >98%	
<b>Clinical Data:</b> Phase 2	
<b>Size:</b> 1 mg, 5 mg, 10 mg	


<b>Gefapixant</b> (AF219; MK-7264)	Cat. No.: HY-101588
<b>Bioactivity:</b> Gefapixant is an orally active P2X3 receptor ( <b>P2X3R</b> ) antagonist with IC <sub>50</sub> s of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors.	
<b>Purity:</b> 99.62%	
<b>Clinical Data:</b> No Development Reported	
<b>Size:</b> 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	


<b>GW791343 dihydrochloride</b>	Cat. No.: HY-15469
<b>Bioactivity:</b> GW791343 2Hcl is a P2X7 allosteric modulator; exhibits species-specific activity and acts as a negative allosteric modulator of human P2X7 (pIC <sub>50</sub> = 6.9 - 7.2).	
<b>Purity:</b> 94.07%	
<b>Clinical Data:</b> No Development Reported	
<b>Size:</b> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	

<b>GW791343 trihydrochloride</b>	Cat. No.: HY-15470
<b>Bioactivity:</b> GW791343 3Hcl is a P2X7 allosteric modulator; exhibits species-specific activity and acts as a negative allosteric modulator of human P2X7 (pIC <sub>50</sub> = 6.9 - 7.2).	
<b>Purity:</b> >98%	
<b>Clinical Data:</b> No Development Reported	
<b>Size:</b> 5 mg, 10 mg, 50 mg	

<b>JNJ-54175446</b>	Cat. No.: HY-117508
<b>Bioactivity:</b> JNJ-54175446 is a potent and selective brain penetrant <b>P2X<sub>7</sub> receptor</b> antagonist, with pIC <sub>50</sub> s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively.	
<b>Purity:</b> >98%	
<b>Clinical Data:</b> No Development Reported	
<b>Size:</b> 500 mg, 250 mg	

<b>KN-62</b>	Cat. No.: HY-13290
<b>Bioactivity:</b> KN-62 is a selective and potent inhibitor of calmodulin-dependent protein kinase II ( <b>CaMK-II</b> ) with IC <sub>50</sub> of 0.9 μM, KN-62 also displays noncompetitive antagonism at <b>P2X<sub>7</sub></b> receptors in HEK293 cells, with an IC <sub>50</sub> value...	
<b>Purity:</b> 99.16%	
<b>Clinical Data:</b> No Development Reported	
<b>Size:</b> 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg	

<b>Lappaconitine</b> (+)-Lappaconitine)	Cat. No.: HY-N0383
<b>Bioactivity:</b> Lappaconitine, isolated from Aconitum sinomontanum Nakai, was characterized as analgesic principle.	
<b>Purity:</b> >98%	
<b>Clinical Data:</b> No Development Reported	
<b>Size:</b> 10 mg, 50 mg, 100 mg	

<b>PSB-12062</b> (N-(p-Methylphenylsulfonyl)phenoxazine)	Cat. No.: HY-101910
<b>Bioactivity:</b> PSB-12062 is a potent and selective <b>P2X<sub>4</sub></b> antagonist with an IC <sub>50</sub> of 1.38 μM for human P2X4.	
<b>Purity:</b> 98.45%	
<b>Clinical Data:</b> No Development Reported	
<b>Size:</b> 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg	